MedWatch

Launch of obesity drug will be Novo Nordisk's fastest ever

Novo Nordisk is gearing up for the launch of the firm's recently-approved obesity drug Wegovy. EVP Camilla Sylvest states the product needs to enter the market "as quickly as possible".

Novo Nordisk EVP, Commercial Strategy and Corporate Affairs, Camilla Sylvest | Photo: Novo Nordisk / PR

After receiving approval from the US Food and Drug Administration (FDA) on Friday, Novo Nordisk is already poised to launch its obesity drug Wegovy over the course of this week. Meanwhile, the Danish pharmaceutical company expects the drug will be available in US pharmacies as of June 18.

Novo Nordisk Executive Vice President for Commercial Strategy and Corporate Affairs, Camilla Sylvest reports this to MedWatch.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs